Last reviewed · How we verify

Enoxaparin Sodium Injection; Rivaroxaban Tablets

Beijing Suncadia Pharmaceuticals Co., Ltd · Phase 2 active Small molecule

Enoxaparin Sodium Injection; Rivaroxaban Tablets is a Anticoagulant Small molecule drug developed by Beijing Suncadia Pharmaceuticals Co., Ltd. It is currently in Phase 2 development for Prophylaxis and treatment of deep vein thrombosis, pulmonary embolism, and stroke prevention in atrial fibrillation.

Enoxaparin sodium injection works by inhibiting Factor Xa and Factor IIa, preventing blood clot formation, while rivaroxaban tablets inhibit Factor Xa directly.

Enoxaparin sodium injection works by inhibiting Factor Xa and Factor IIa, preventing blood clot formation, while rivaroxaban tablets inhibit Factor Xa directly. Used for Prophylaxis and treatment of deep vein thrombosis, pulmonary embolism, and stroke prevention in atrial fibrillation.

At a glance

Generic nameEnoxaparin Sodium Injection; Rivaroxaban Tablets
SponsorBeijing Suncadia Pharmaceuticals Co., Ltd
Drug classAnticoagulant
TargetFactor Xa, Factor IIa
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 2

Mechanism of action

Enoxaparin sodium injection is a low molecular weight heparin that exerts its anticoagulant effect by binding to antithrombin III, thereby inhibiting Factor Xa and Factor IIa. Rivaroxaban tablets, on the other hand, directly inhibits Factor Xa, a key enzyme in the coagulation cascade. This dual mechanism of action helps prevent the formation of blood clots and reduce the risk of stroke and other thromboembolic events.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Enoxaparin Sodium Injection; Rivaroxaban Tablets

What is Enoxaparin Sodium Injection; Rivaroxaban Tablets?

Enoxaparin Sodium Injection; Rivaroxaban Tablets is a Anticoagulant drug developed by Beijing Suncadia Pharmaceuticals Co., Ltd, indicated for Prophylaxis and treatment of deep vein thrombosis, pulmonary embolism, and stroke prevention in atrial fibrillation.

How does Enoxaparin Sodium Injection; Rivaroxaban Tablets work?

Enoxaparin sodium injection works by inhibiting Factor Xa and Factor IIa, preventing blood clot formation, while rivaroxaban tablets inhibit Factor Xa directly.

What is Enoxaparin Sodium Injection; Rivaroxaban Tablets used for?

Enoxaparin Sodium Injection; Rivaroxaban Tablets is indicated for Prophylaxis and treatment of deep vein thrombosis, pulmonary embolism, and stroke prevention in atrial fibrillation.

Who makes Enoxaparin Sodium Injection; Rivaroxaban Tablets?

Enoxaparin Sodium Injection; Rivaroxaban Tablets is developed by Beijing Suncadia Pharmaceuticals Co., Ltd (see full Beijing Suncadia Pharmaceuticals Co., Ltd pipeline at /company/beijing-suncadia-pharmaceuticals-co-ltd).

What drug class is Enoxaparin Sodium Injection; Rivaroxaban Tablets in?

Enoxaparin Sodium Injection; Rivaroxaban Tablets belongs to the Anticoagulant class. See all Anticoagulant drugs at /class/anticoagulant.

What development phase is Enoxaparin Sodium Injection; Rivaroxaban Tablets in?

Enoxaparin Sodium Injection; Rivaroxaban Tablets is in Phase 2.

What are the side effects of Enoxaparin Sodium Injection; Rivaroxaban Tablets?

Common side effects of Enoxaparin Sodium Injection; Rivaroxaban Tablets include Major bleeding, Hemorrhage, Thrombocytopenia.

What does Enoxaparin Sodium Injection; Rivaroxaban Tablets target?

Enoxaparin Sodium Injection; Rivaroxaban Tablets targets Factor Xa, Factor IIa and is a Anticoagulant.

Related